Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Advanced Concepts in Human Immunology: Prospects for Disease Control / / edited by Pooja Jain, Lishomwa C. Ndhlovu
| Advanced Concepts in Human Immunology: Prospects for Disease Control / / edited by Pooja Jain, Lishomwa C. Ndhlovu |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (XVIII, 403 p. 16 illus., 5 illus. in color.) |
| Disciplina | 616.079 |
| Soggetto topico |
Immunology
Vaccines Infectious diseases Cancer - Research Immunologia Sistema immunitari Malalties autoimmunitàries Càncer Al·lèrgia Malalties neurodegeneratives Malalties infeccioses Vaccine Infectious Diseases Cancer Research |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-33946-7 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Human Chronic Viruses: Pathogenesis, host response, and treatment -- 2. Defining the Role of Immunoproteomics in Human Immunotherapy -- 3. Microbiome and Cellular Players in Type 1 Diabetes: from Pathogenesis to Protection -- 4. Immune Mechanisms, Pathology, and Management of Allergic Ocular Diseases -- 5. Dendritic Cell-regulated T Cell Immunity and Tolerance against Acute Myeloid Leukemia -- 6. Perspectives on the Role of T cell Negative Immune Checkpoint Receptors in Health and Disease -- 7. Neuroprotective Immunity for Neurodegenerative and Neuroinfectious Diseases -- 8. Polycystic Ovary Syndrome: An overview of a complex, heterogeneous genetic condition. |
| Record Nr. | UNINA-9910416101503321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Autoimmune Disease Diagnosis : Systemic and Organ-specific Diseases / / edited by Yehuda Shoenfeld, Ricard Cervera, Gerard Espinosa, M. Eric Gershwin
| Autoimmune Disease Diagnosis : Systemic and Organ-specific Diseases / / edited by Yehuda Shoenfeld, Ricard Cervera, Gerard Espinosa, M. Eric Gershwin |
| Autore | Shoenfeld Yehuda |
| Edizione | [2nd ed. 2024.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 |
| Descrizione fisica | 1 online resource (1829 pages) |
| Disciplina | 616.723 |
| Altri autori (Persone) |
CerveraRicard
EspinosaGerard GershwinM. Eric |
| Collana | Medicine Series |
| Soggetto topico |
Rheumatology
Immunology Internal medicine Internal Medicine Malalties autoimmunitàries |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
9783031698958
3031698959 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part 1. CLASSICAL SYSTEMIC AUTOIMMUNE DISEASES -- 1. Systemic Lupus Erythematosus -- 2. Antiphospholipid Syndrome -- 3. Rheumatoid Arthritis -- 4. Diagnostic and Classification Criteria for Juvenile Idiopathic Arthritis -- 5. Adult- Onset Still's Disease -- 6. Systemic Sclerosis -- 7. Sjögren Disease -- 8. Mixed Connective Tissue Disease -- 9. Relapsing polychondritis -- 10. Raynaud’s Phenomenon (RP) -- 11. DRUG-INDUCED AUTOIMMUNITY -- 12. Polyautoimmunity and the Multiple Autoimmune Syndromes -- II. SYSTEMIC VASCULITIS -- 13. Giant Cell Arteritis -- 14. Polymyalgia Rheumatica -- 15. Takayasu Arteritis -- 16. Polyarteritis Nodosa -- 17. Microscopic Polyangiitis -- 18. Granulomatosis with polyangiitis -- 19. Eosinophilic Granulomatosis with Polyangiitis (EGPA, Churg-Strauss) -- 20. Buerger's Disease -- 21. Behcet’s disease -- 22. Susac Syndrome -- 23. Anti-Glomerular Basement Membrane disease (Goodpasture’s Syndrome) -- 24. Kawasaki Disease -- 25. Cogan Syndrome -- 26. Immunoglobulin A Vasculitis -- 27. Cryoglobulinemic vasculitis -- 28. Hypocomplementemic Urticarial Vasculitis (ANTI-C1g Vasculitis) -- 29. Single Organ Vasculitis.-III. IDIOPATHIC INFLAMMATORY MYOPATHIES -- 30. Polymyositis -- 31. Dermatomyositis -- 32. Sporadic Inclusion Body Myositis -- 33. Antisynthetase Syndrome -- 34. Immune-mediated Necrotizing Myopathy -- 35. Granulomatous Myositis -- 36. Eosinophilic Myositis -- 37. Eosinophilic Fasciitis -- IV. OTHER IMMUNE-MEDIATED SYSTEMIC DISEASES -- 38. Sarcoidosis -- 39. Spondyloarthropathies -- 40. Diagnostic and Classification Criteria in Familial Mediterranean Fever -- 41. VEXAS syndrome -- 42.Diagnostic criteria for Fibromyalgia modern concept -- 43. IgG4-related disease -- 44. ASIA Syndrome -- 45. Immune adverse effects induced by checkpoint Inhibitors -- V. ENDOCRINE AND REPRODUCTIVE AUTOIMMUNE DISEASES -- 46. Hashimoto’s thyroiditis -- 47. ATROPHIC AUTOIMMUNE THYROIDITIS -- 48. Subacute Thyroiditis -- 49. GRAVES DISEASE -- 50.Postpartum thyroiditis -- 51. Autoimmune Diabetes Mellitus -- 52. Autoimmune Adrenalitis -- 53. Autoimmune Hypophysitis -- 54. Autoimmune Parathyroid Disease -- 55. Autoimmune Polyendocrine Syndromes -- 56. Endometriosis -- 57.Autoimmune Ovarian Insufficiency -- 58. Autoimmune Orchitis -- VI. HEPATOBILIARY AND PANCREATIC AUTOIMMUNE DISEASES -- 59. Autoimmune Hepatitis -- 60. Diagnosis of Primary Biliary Cholangitis -- 61. Primary Sclerosing Cholangitis: Diagnosis and Therapy -- 62. Autoimmune Pancreatitis -- VII. GASTROINTESTINAL AUTOIMMUNE DISEASES -- 63. Autoimmune Gastritis -- 64. Ulcerative Colitis -- 65. Crohn Disease -- 66. Celiac Disease -- VIII. CUTANEOUS AUTOIMMUNE DISEASES -- 67. Cutaneous Lupus Erythematosus -- 68. Pemphigus and Bullous Pemphigoid -- 69. Vitiligo -- 70. Psoriasis and Psoriatic Arthropathy -- 71. Autoimmune Alopecia -- 72. Hidradenitis suppurativa -- 73. Other Immune-mediated Dermatosis (Liquen Planus, Erythema Multiforme, Toxic Epidermic Necrolysis, Graft versus Host Reaction) -- IX. CARDIOVASCULAR AND PULMONARY AUTOIMMUNE DISEASES -- 74. Autoimmune Dilated Cardiomyopathy -- 75. Rheumatic Fever -- 76. Accelerated Atherosclerosis in Autoimmune Diseases -- 77. Idiopathic Interstitial Pneumonias -- 78. Pulmonay Arterial Hypertension -- X. NEUROLOGICAL AUTOIMMUNE DISEASES -- 79. Diagnostic criteria for Multiple Sclerosis -- 80. Myasthenia Gravis -- 81. Diagnostic criteria of paraneoplastic neurological syndromes -- 82. Guillain-Barre Syndrome and Other Immune-Mediated Neuropathies -- 83. Transverse Myelitis and Optic Neuromyelitis (Devic Syndrome) -- 84. Central Nervous System Vasculitis -- 85. Autoimmune Chorea -- 86. Autoimmune Sensorineural Hearing Loss -- 87. Autoimmune Encephalitis -- 88. Autoimmune Dysautonomia -- 89. Cerebellar Autoimmune Diseases -- 90. Autoimmune Disturbances of Sleeping -- 91. Autoimmune Stiff person Syndrome -- XI. OCULAR AUTOIMMUNE DISEASES -- 92. Autoimmune Retinopathies -- 93. Autoimmune Uveitis -- 94. Vogt-Koyanagi Harada Disease -- 95. Orbital Myositis -- XII. RENAL AUTOIMMUNE DISEASES -- 97. Membranous Nephropathy -- 98. Minimal change disease -- 99. Focal and Segmental Glomerulosclerosis -- 100. Membranoproliferative Glomerulonephritis -- 101. Acute tubulointerstitial nephritis -- 102.Atypical Hemolytic Uremic Syndrome -- XIII. HEMATOLOGIC AUTOIMMUNE DISEASES.-103. Autoimmune Hemolytic Anemia -- 104. Pernicious Anemia -- 105. Idiopathic Aplastic Anemia -- 106. Acquired Adult Pure Red-cell Aplasia -- 108. Autoimmune Neutropenia -- 109. Immune thrombocytopenia -- 110. Thrombotic Thrombocytopenic Purpura and Other Thrombotic Microangiopathic Hemolytic Anemias -- 111. Heparin-induced Thrombocytopenia -- 112. Autoimmune Coagulopathies. |
| Record Nr. | UNINA-9910921006703321 |
Shoenfeld Yehuda
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Passion for Excellence : My Lifelong Journey into Medicine and Public Service / / by Haralampos M. Moutsopoulos
| Passion for Excellence : My Lifelong Journey into Medicine and Public Service / / by Haralampos M. Moutsopoulos |
| Autore | Moutsopoulos H. M (Haralampos M.) |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 |
| Descrizione fisica | 1 online resource (192 pages) |
| Disciplina |
296.188362197954
610.92 |
| Collana | Springer Biographies |
| Soggetto topico |
Rheumatology
Autoimmunity Sociology - Biographical methods Biographical Research Malalties autoimmunitàries Síndrome de Sjögren Investigació Metges |
| Soggetto genere / forma |
Biografies
Llibres electrònics |
| ISBN | 9783031141287 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Coming of Age -- 2. Student Years -- 3. Young Physician -- 4. In the Army -- 5. Public Health Service. |
| Record Nr. | UNINA-9910620197203321 |
|
Moutsopoulos H. M (Haralampos M.)
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The Role of Microbes in Autoimmune Diseases : New Mechanisms of Microbial Initiation of Autoimmunity / / by Ahed J. Alkhatib
| The Role of Microbes in Autoimmune Diseases : New Mechanisms of Microbial Initiation of Autoimmunity / / by Ahed J. Alkhatib |
| Autore | Alkhatib Ahed J. |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2022 |
| Descrizione fisica | 1 online resource (121 pages) |
| Disciplina | 616.97801 |
| Soggetto topico |
Immunology
Human physiology Neurosciences Internal medicine Microbiology Human Physiology Neuroscience Internal Medicine Malalties autoimmunitàries Microbiologia mèdica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 9789811911620 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1: Immunology: Principles and Applications -- Chapter 2: Immunology and Microbes -- Chapter 3: Types of hypersensitivities (updates) -- Chapter 4: Autoimmunity -- Chapter 5: Autoimmunity and Diseases -- Chapter 6: Intestinal Flora as Initiatives of Autoimmunity -- Chapter 7: Our Perception of Autoimmunity and Microbes. |
| Record Nr. | UNINA-9910568277303321 |
|
Alkhatib Ahed J.
|
||
| Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases : Volume I: Liver, Skin, Thyroid, Rheumatic & Myopathic Diseases / / edited by Mitesh Kumar Dwivedi, N. Amaresan, E. Helen Kemp, Yehuda Shoenfeld
| Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases : Volume I: Liver, Skin, Thyroid, Rheumatic & Myopathic Diseases / / edited by Mitesh Kumar Dwivedi, N. Amaresan, E. Helen Kemp, Yehuda Shoenfeld |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2022 |
| Descrizione fisica | 1 online resource (680 pages) |
| Disciplina | 616.978 |
| Soggetto topico |
Immunology
Diseases - Causes and theories of causation Autoimmunity Medicine - Research Biology - Research Pathogenesis Biomedical Research Malalties autoimmunitàries Ecologia microbiana Etiologia Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-19-1946-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part I: OVERVIEW OF INFECTIOUS MICROORGANISMS & MICROBIOTA IN INDUCING AUTOIMMUNIT -- Chapter 1. The Concept of Infection Triggered autoimmunity -- Chapter 2. The interaction of gut microbiota with immune system and their effects on immune cell development and function -- Chapter 3. The Link between gut microbiota and autoimmune diseases -- Chapter 4. The factors influencing gut microbiota in autoimmune diseases -- PART II: MICROORGANISMS IN PATHOGENESIS & MANAGEMENT OF AUTOIMMUNE LIVER DISEASES -- Chapter 5. Microorganisms in pathogenesis and management of Autoimmune hepatitis (AIH) -- Chapter 6. Microorganisms in pathogenesis and management of Primary Biliary Cholangitis -- Chapter 7. Microorganisms in pathogenesis and management of Primary biliary cholangitis -- PART III: MICROORGANISMS IN PATHOGENESIS & MANAGEMENT OF SKIN AUTOIMMUNE DISEASES -- Chapter 8. Microorganisms in pathogenesis and management of Psoriasis -- Chapter 9. Microorganisms in pathogenesis and management of Vitiligo -- Chapter 10. Microorganisms in pathogenesis and management of Scleroderma (systemic sclerosis) -- Chapter 11. Microorganisms in pathogenesis and management of Atopic Dermatitis -- Chapter 12. Microorganisms in pathogenesis and management of Pemphigus Vulgaris -- Chapter 13. Microorganisms in pathogenesis and management of Bullous pemphigoid -- PART IV: MICROORGANISMS IN PATHOGENESIS & MANAGEMENT OF AUTOIMMUNE THYROID DISEASES -- Chapter 14. Microorganisms in pathogenesis and management of Graves's Disease -- Chapter 15. Microorganisms in pathogenesis and management of Hashimoto's Thyroiditis -- PART V: MICROORGANISMS IN PATHOGENESIS & MANAGEMENT OF AUTOIMMUNE RHEUMATIC DISEASES -- Chapter 16. Microorganisms in pathogenesis and management of Rheumatoid Arthritis (RA) -- Chapter 17. Microorganisms in pathogenesis and management of Spondyloarthritis -- Chapter 18. Microorganisms in pathogenesis and management of Ankylosing spondylitis (AS) -- Chapter 19. Microorganisms in pathogenesis and management of Psoriasis Arthritis (PsA) -- Chapter 20. Microorganisms in pathogenesis and management of Systemic Lupus Erythematosus (SLE) -- Chapter 21. Microorganisms in pathogenesis and management of Sjogren’s syndrome -- Chapter 22. Autoimmune Diseases Associated with Chikungunya Infection -- PART VI: MICROORGANISMS IN PATHOGENESIS & MANAGEMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES -- Chapter 23. Microorganisms in pathogenesis and management of dermatomyositis (DM) and polymyositis (PM) -- Chapter 24. Microorganisms in pathogenesis and management of necrotizing autoimmune myopathy (NAM) and inclusion body myositis (IBM). |
| Record Nr. | UNINA-9910586576503321 |
| Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Scleroderma : From Pathogenesis to Comprehensive Management / / edited by Yannick Allanore, John Varga, Christopher P. Denton, Masataka Kuwana, Lorinda Chung, Ami A. Shah
| Scleroderma : From Pathogenesis to Comprehensive Management / / edited by Yannick Allanore, John Varga, Christopher P. Denton, Masataka Kuwana, Lorinda Chung, Ami A. Shah |
| Autore | Allanore Yannick |
| Edizione | [3rd ed. 2024.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2024 |
| Descrizione fisica | 1 online resource (XXI, 835 p.) |
| Disciplina | 616.544 |
| Soggetto topico |
Rheumatology
Malalties autoimmunitàries Reumatologia |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-031-40658-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Preface -- . Foreword -- Section 1: Introduction. -- 1. Historical perspective of scleroderma -- Section 2: Epidemiology, Genetics and Classification. -- 2. Epidemiology, Environmental and Infectious Risk Factors -- 3. Influence of ethnicity and sex bias in systemic sclerosis -- 4. Genetic Factors -- 5. Classification and Disease Subsets in Clinical Practice -- 6. Clustering and evolving concepts for subclassification -- 7. The Clinical Aspects of Autoantibodies -- 8. Systemic sclerosis overlap syndromes -- 9. Juvenile Localized and Systemic Scleroderma -- 10. Morphea (Localized scleroderma) -- Section 3: The Biological Basis of Systemic Sclerosis. -- 11. Scleroderma Mimics -- 12. Introduction: The Etiopathogenesis of Systemic Sclerosis - an Integrated Overview -- 13. Pathology of Systemic Sclerosis -- 14. Inflammation And Immunity In Systemic Sclerosis -- 15. Autoantibodies as Markers and Possible Mediators of Scleroderma Pathogenesis -- 16. Mechanisms of Vascular Disease -- 17. Biomarkers in Systemic Sclerosis -- 18. Cellular and molecular mechanisms of fibrosis in systemic sclerosis -- 19. Overview of Animal Models -- Section 4: Cardiovascular Manifestations and Management. -- 20. Overview of management and outcome assessment in systemic sclerosis -- 21. Raynaud’s Phenomenon, Digital Ulcers and Nailfold Capillaroscopy -- 22. Renal crisis and other renal manifestations -- 23. Cardiac Involvement: Evaluation And Management -- Section 5: Pulmonary Manifestations and Management. -- 24. Overview of lung involvement -- 25. Clinical assessment of ILD -- 26. Lung Imaging Perspective in Scleroderma -- 27. Treatment of Interstitial Lung Disease in systemic sclerosis -- 28. Pathogenesis of Pulmonary Arterial Hypertension -- 29. Clinical Assessment of Pulmonary Hypertension -- 30. The management of pulmonary arterial hypertension in the setting of systemic sclerosis -- Section 6: Gastrointestinal Manifestations and Management. -- 31. Overview of gastrointestinal tract involvement -- 32. UpperGastrointestinal Tract: Manifestations of Systemic Sclerosis -- 33. Lower Gastrointestinal Tract Involvement: Understanding the Interplay of Motility, the Microbiome and Nutrition -- Section 7: Skin, Musculoskeletal and Other Complications. -- 34. Evaluation and Management of Skin Disease -- 35. Calcinosis -- 36. Tendons, Joints, and Bone -- 37. Skeletal Muscle Involvement -- 38. Cancer in Systemic Sclerosis -- 39. Overlooked Manifestations -- 40. Pregnancy -- 41. Vaccinations in Patients with Systemic Sclerosis -- Section 8: Management and Outcome Assessment -- 42. Management Of Progressive Skin Involvement In Diffuse Scleroderma -- 43. Hematopoietic stem cell transplantation -- 44. Immune targeted therapies in SSc. -- 45. Physical and Occupational Therapy -- 46. Psychosocial Issues and Care for Patients with Systemic Sclerosis -- Section 9: Case Studies: Approach to Complex Clinical Problems. -- 47. Measuring Disease Activity and Outcomes in Clinical Trials -- 48. Evolving clinical trial design andinnovative approaches -- 49. Drug Development and Regulatory Considerations for Systemic Sclerosis Therapies -- 50. Managing the Ischemic Finger in Scleroderma -- 51. Scleroderma Renal Crisis: a case study -- 52. Rapid diffuse skin disease with progressive joint contractures -- 53. Management of the Scleroderma Patient with Pulmonary Arterial Hypertension Failing Initial Therapy -- 54. Pseudo-obstruction with malabsorption and malnutrition -- 55. Progressive Interstitial Lung Disease Non-Responsive to Immunosuppressive Therapy -- 56. Body Image Distress in Scleroderma -- 57. Managing Complicated Digital Ulcers -- 58. Lower Limb Ulceration. |
| Record Nr. | UNINA-9910851982803321 |
|
Allanore Yannick
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Urticaria and Angioedema / / edited by Torsten Zuberbier, Clive Grattan, Marcus Maurer
| Urticaria and Angioedema / / edited by Torsten Zuberbier, Clive Grattan, Marcus Maurer |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (256 pages) |
| Disciplina | 616.5 |
| Soggetto topico |
Dermatology
Allergy Pediatrics Edema angioneuròtic Urticària Malalties autoimmunitàries |
| Soggetto genere / forma | Llibres electrònics. |
| ISBN | 3-030-84574-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface to the First Edition -- Preface -- Contents -- Contributors -- 1: History of Urticaria -- 1.1 Introduction -- 1.2 The Cellular and Molecular Basis of Urticaria: First Steps -- 1.3 The Enigma of Chronic "Idiopathic" Urticaria -- 1.4 Treatment of Urticaria: Antihistamines -- References -- 2: Aetiopathogenesis of Urticaria -- 2.1 Lessons Learned from Histopathology -- 2.2 A Central Role for the Mast Cell -- 2.3 Mast Cell Mediators of Urticaria -- 2.3.1 Histamine -- 2.3.2 Cysteinyl Leukotrienes and Platelet Activating Factor -- 2.4 Involvement of Other Inflammatory Cells in Urticaria -- 2.5 The Role of Bradykinin in Angioedema -- 2.6 What Causes Mast Cell Mediator Release in the First Place? -- 2.7 Tests for Autoimmune and Autoallergic Urticaria -- 2.7.1 Autologous Serum Skin Test (ASST) -- 2.7.2 Basophil Activation Assays -- 2.7.3 Immunoassays for Autoantibodies in Autoimmune CSU -- 2.8 Conclusions -- References -- 3: Classification and Diagnosis of Urticaria -- 3.1 Definition -- 3.2 Histology -- 3.3 Classification of Urticaria on the Basis of Its Symptoms, Duration, Frequency, and Causes -- 3.4 Diagnosis of Urticaria -- 3.4.1 Diagnostic Work Up in Acute Urticaria -- 3.4.2 The Diagnostic Work Up in CU -- 3.4.2.1 Assessment of Disease Activity Impact and Control -- References -- 4: Impact of Chronic Urticaria and How to Measure It -- 4.1 What Makes Chronic Urticaria a Burdensome Condition -- 4.1.1 Physical, Social, and Emotional Burden in Chronic Spontaneous Urticaria -- 4.1.2 Itch, Sleep Impairment, and Psychiatric Comorbidities in Chronic Spontaneous Urticaria -- 4.1.3 Impairment of Daily Activities and Work Productivity in Chronic Spontaneous Urticaria -- 4.1.4 Disease Burden in Chronic Inducible Urticaria -- 4.2 Extent, Pattern, and Drivers of Disease Burden.
4.2.1 HRQoL Impairment in Chronic Spontaneous Urticaria -- 4.2.2 Drivers of HRQoL in chronic spontaneous urticaria -- 4.2.3 HRQoL Impairment in Chronic Inducible Urticaria -- 4.3 How to Assess Disease Burden in CSU -- 4.3.1 The Use of PROMs Improves Chronic Urticaria Management -- 4.3.2 What PROMs Should Be Used in Chronic Spontaneous Urticaria -- 4.3.3 What PROMs Should Be Used in Chronic Inducible Urticaria -- References -- 5: Acute Urticaria -- 5.1 Definition -- 5.2 Epidemiology -- 5.3 Clinical Aspects -- 5.4 Aetiology -- 5.5 Natural Course -- 5.6 Diagnosis -- 5.7 Treatment -- References -- 6: Chronic Spontaneous Urticaria -- 6.1 Definition -- 6.2 Clinical Picture -- 6.3 Epidemiology -- 6.4 Etiopathogenesis -- 6.4.1 Autoallergy and Autoimmunity, Causes of CSU -- 6.4.2 Autoimmunity -- 6.4.3 Stress, Infections, and Food Intolerance, Modulators of CSU -- 6.5 Diagnostic Workup -- 6.6 Therapy -- References -- 7: Chronic Spontaneous Urticaria and Comorbidities -- 7.1 Introduction -- 7.2 Chronic Inducible Urticaria -- 7.3 Mental Disorders -- 7.4 Autoimmune Diseases -- 7.5 Infection -- 7.5.1 Bacterial Infection -- 7.5.2 Parasitic Infection -- 7.5.3 Viral Infection -- 7.5.4 Fungal Infection -- 7.6 Allergic Diseases -- 7.7 Malignancy -- 7.8 Metabolic Syndrome -- References -- 8: Inducible Urticarias -- 8.1 Introduction -- 8.2 Symptomatic Dermographism -- 8.2.1 Definition and Clinical Picture -- 8.2.2 Pathogenesis -- 8.2.3 Diagnosis and Differential Diagnosis -- 8.2.4 Treatment and Prognosis -- 8.3 Cold Urticaria -- 8.3.1 Definition and Clinical Picture -- 8.3.2 Pathogenesis -- 8.3.3 Diagnosis and Differential Diagnosis -- 8.3.4 Treatment and Prognosis -- 8.4 Delayed Pressure Urticaria -- 8.4.1 Definition and Clinical Picture -- 8.4.2 Pathogenesis -- 8.4.3 Diagnosis and Differential Diagnosis. 8.4.4 Treatment and Prognosis -- 8.5 Solar Urticaria -- 8.5.1 Definition and Clinical Picture -- 8.5.2 Pathogenesis -- 8.5.3 Diagnosis and Differential Diagnosis -- 8.5.4 Treatment and Prognosis -- 8.6 Heat Urticaria -- 8.6.1 Definition and Clinical Picture -- 8.6.2 Pathogenesis -- 8.6.3 Diagnosis and Differential Diagnosis -- 8.6.4 Treatment and Prognosis -- 8.7 Vibratory Angioedema -- 8.7.1 Definition and Clinical Picture -- 8.7.2 Pathogenesis -- 8.7.3 Diagnosis and Differential Diagnosis -- 8.7.4 Treatment and Prognosis -- 8.8 Cholinergic Urticaria -- 8.8.1 Definition and Clinical Picture -- 8.8.2 Pathogenesis -- 8.8.3 Diagnosis and Differential Diagnosis -- 8.8.4 Treatment and Prognosis -- 8.9 Contact Urticaria -- 8.9.1 Definition and Clinical Picture -- 8.9.2 Pathogenesis -- 8.9.3 Diagnosis and Differential Diagnosis -- 8.9.4 Treatment and Prognosis -- 8.10 Aquagenic Urticaria -- 8.10.1 Definition and Clinical Picture -- 8.10.2 Pathogenesis -- 8.10.3 Diagnosis and Differential Diagnosis -- 8.10.4 Treatment and Prognosis -- References -- 9: Angioedema -- 9.1 Introduction -- 9.2 Differential Diagnosis -- 9.2.1 Pseudo Angioedema (Figs. 9.2 and 9.3) -- 9.2.2 Angioedema Associated with Systemic Syndromes -- 9.2.3 Diagnostic Strategy for Isolated Angioedema (Table 9.1) -- 9.3 Mast Cell Angioedema (Histaminergic, …) -- 9.3.1 Isolated Allergic Angioedema -- 9.3.2 Spontaneous MC-AE (More Frequent) -- 9.3.3 Non-steroid Anti-inflammatory Drugs Induced AE (NSAID-AE) -- 9.4 Bradykinin Mediated AE (Fig. 9.4) -- 9.4.1 Clinical Description -- 9.4.1.1 Abdominal Localization -- 9.4.1.2 Upper Airways Localization -- 9.4.1.3 Erythema Marginatum (Photo 9.2) -- 9.4.2 Pathophysiology (Fig. 9.2) -- 9.4.3 BK-AE with C1Inh Deficiency (Fig. 9.4) -- 9.4.3.1 Hereditary Angioedema (HAE Type I/II). 9.4.3.2 Acquired AE (Type I/II) -- 9.4.4 BK-AE with Normal C1Inh (Fig. 9.4) -- 9.4.4.1 Hereditary AE with Normal C1Inh (Previously Type III) [44] -- 9.4.4.2 Drug Induced BK-AE (Mainly Angiotensin-Converting Enzyme Inhibitor (ACEi)) -- 9.5 Conclusion -- References -- 10: Management Principles in Urticaria -- 10.1 Identification and Elimination of Underlying Causes -- 10.2 Drugs -- 10.3 Infection -- 10.4 Food Intolerance -- 10.5 Physical Stimuli -- 10.6 Lifestyle Adjustments -- 10.7 Inducing Tolerance -- 10.8 Pharmacological Treatment -- 11: Antihistamines -- 11.1 Introduction -- 11.2 The Histamine H1-Receptor -- 11.3 H1-Antihistamines and the Central Nervous System -- 11.4 H1-Antihistamines and Cardiotoxicity -- 11.5 H1-Antihistamines in Urticaria -- 11.5.1 Speed of Onset of Action and Duration of Action -- 11.5.2 Efficacy -- 11.5.3 Clinical Usage -- 11.6 Conclusions -- References -- 12: Omalizumab in the Treatment of Urticaria -- 12.1 Bioavailability, Metabolism and Elimination -- 12.2 Mechanisms of Action of Omalizumab in CSU -- 12.3 Common Adverse Effects -- 12.4 Omalizumab in the Treatment of Chronic Spontaneous Urticaria: Clinical Trials -- 12.5 Omalizumab in the Treatment of Chronic Spontaneous Urticaria: Real-world Data -- 12.6 Markers that Predict and Tools that Help to Monitor Treatment Responses to Omalizumab in Patients with CSU -- 12.7 Use in Pregnancy and Breast Feeding -- 12.8 Home Therapy -- 12.9 Future Developments -- 12.10 Current Positioning of Omalizumab in Local and International Guidelines -- References -- 13: Other Interventions for Chronic Urticaria -- 13.1 Low-Evidence Pharmacological Interventions in Chronic Urticaria -- 13.1.1 Anti-inflammatory Sulphones -- 13.1.1.1 Dapsone -- Evidence for Dapsone in Urticaria -- Dose and Length of Treatment -- Interactions with Other Medicines. Checks During Treatment -- Contraindications to Treatment -- Possible Side Effects of Treatment -- Summary -- 13.1.1.2 Sulphasalazine -- Evidence for Sulphasalazine in Urticaria -- Dose and Length of Treatment -- Possible Side Effects of Treatment -- Interactions with Other Medicines -- Checks During Treatment -- Reasons for Avoiding It -- Summary -- 13.1.2 Tranexamic Acid -- 13.1.2.1 Evidence for Tranexamic Acid in Urticaria -- 13.1.2.2 Dose and Length of Treatment -- 13.1.2.3 Possible Side Effects of Treatment -- 13.1.2.4 Interactions with Other Medicines -- 13.1.2.5 Checks During Treatment -- 13.1.2.6 Contraindications to Treatment -- 13.1.2.7 Summary -- 13.1.3 Montelukast -- 13.1.3.1 Evidence for Using Montelukast in Urticaria -- 13.1.3.2 Dose and Length of Treatment -- 13.1.3.3 Possible Side Effects of Treatment -- 13.1.3.4 Interactions with Other Medicines and Reasons for Avoiding It -- 13.1.3.5 Checks During Treatment -- 13.1.3.6 Summary -- 13.1.4 H2 Antihistamines -- 13.1.4.1 Evidence for Using H2 Antihistamines in Urticaria -- 13.1.5 Immunosuppressives -- 13.1.5.1 Ciclosporin -- Evidence for Using Ciclosporin in Urticaria -- Dose and Length of Treatment -- Possible Side Effects of Treatment -- Checks Before and During Treatment -- Interactions with Other Medicines -- Cautions and Contraindications -- Summary -- 13.1.5.2 Methotrexate -- Evidence for Using Methotrexate in Urticaria -- Dose and Length of Treatment -- Possible Side effects of Treatment -- Checks Before and During Treatment -- Interactions with Other Medicines -- Cautions and Contraindications -- Summary -- 13.1.5.3 Mycophenolate Mofetil -- Evidence for Using Mycophenolate in Urticaria -- Dose and Length of Treatment -- Possible Side effects of Treatment -- Interactions with Other Medicines -- Checks During Treatment -- Contraindications to Treatment. Summary. |
| Record Nr. | UNINA-9910506395403321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Women's Health in Autoimmune Diseases / / edited by Shefali Khanna Sharma
| Women's Health in Autoimmune Diseases / / edited by Shefali Khanna Sharma |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (XIII, 278 p. 34 illus., 23 illus. in color.) |
| Disciplina | 616.9780082 |
| Soggetto topico |
Gynecology
Rheumatology Malalties autoimmunitàries Ginecologia Reumatologia |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-15-0114-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. Does genetics play a role in Auto-immune Diseases? -- Chapter 2. Influence of Gender on Auto-Immune Rheumatic diseases -- Chapter 3. Sex Bias in Systemic Lupus Erythematosus and Sjögren’s Syndrome -- Chapter 4. Antibody Estimation in Pregnancy -- Chapter 5. Antiphospholipid Antibody Syndrome (APS) -- Chapter 6. Fertility and Pregnancy in Auto-Immune Diseases -- Chapter 7. Update on use of Biologic and Targeted Synthetic Drugs in Pregnancy -- Chapter 8. Managing menstrual Irregularities in Auto-Immune Diseases -- Chapter 9. Fertility Preservation in Women with Auto-Immune Diseases Treated with Gonadotoxic Agents -- Chapter 10. Pre conception care and Counselling in Auto-Immune Disorders -- Chapter 11. Effect of Pregnancy on Auto-Immune Diseases -- Chapter 12. Management of Lupus Flare during Pregnancy -- Chapter 13. Lupus Nephritis & Pregnancy -- Chapter 14. Pregnancy in Systemic Vasculitis -- Chapter 15. Managing APLA during Pregnancy -- Chapter 16. Scleroderma and Pregnancy -- Chapter 17. Management and Monitoring of anti-Ro/La positive mother -- Chapter 18. Management of Sjögren’s Syndrome during Pregnancy -- Chapter 19. Maternal Mortality and Morbidity in Auto-Immune Diseases -- Chapter 20. Anti-Rheumatic Drugs in Pregnancy -- Chapter 21. Non- Steroidal Anti- Inflammatory Drugs Use During Pregnancy and Lactation: Effects on Mother and Child -- Chapter 22. Management of Neonate with Heart Block -- Chapter 23. Compilation of Indian data -- Chapter 24. Osteoporosis in Autoimmune Rheumatic Diseases -- Chapter 25. Menopause in Auto-Immune Disease and Hormone Replacement Therapy -- Chapter 26. Fibromyalgia.-. |
| Record Nr. | UNINA-9910411937603321 |
| Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||